CTOs on the Move

Greenway Medical Technologies, Inc.

www.greenwaymedical.com

 
Greenway Medical Technologies provides the latest in ambulatory healthcare business solutions and services to 20000 healthcare providers and professionals nationwide, in 30 specialties and subspecialties, by enhancing the delivery of patient care
  • Number of Employees: 0-25
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Dosist

Recognized as a disruptor in the health industry, dosist is setting a new standard in access to natural plant-based health and wellness solutions. Through our award-winning products, we provide consistent, targeted formulas and precise dosage, allowing people to experience the benefits of cannabis-based therapy in an effective and predictable way.

Modern Concepts Medical

Modern Concepts Medical is a Montebello, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kemberton

Kemberton is a leading provider of technology-enabled revenue cycle management services to hospitals for complex claims. We specialize in the management and collection of workers compensation, motor vehicle accident claims, veteran administration and the resolution of insurance denials for hospitals and physician practice groups. Kemberton helps accelerate collection times and maximize reimbursements for over 300 hospital clients across 35 states, resulting in over $1.5 billion dollars of incremental cash payments for our clients.

Cherry Optical Inc

Cherry Optical Inc is a Melvindale, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.